Who are Opus Genetics, Inc.'s main suppliers?

Opus Genetics, Inc. (IRD) key suppliers include: OPCM-SA-LLC, APEXIAN-PHARMACEUTICALS-INC, MASSACHUSETTS-EYE-AND-EAR-INFIRMARY, PENN-AND-UF, Myriad Genetics, Inc. and 5 more. View the full supplier network at chainsifter.com/chain/IRD.

Who are Opus Genetics, Inc.'s major customers?

Opus Genetics, Inc. (IRD) key customers include: VIATRIS, Myriad Genetics, Inc., Myriad Genetics, Inc., Ocular Therapeutix, Inc., Ocular Therapeutix, Inc. and 15 more. View the full customer network at chainsifter.com/chain/IRD.

What sector is Opus Genetics, Inc. in?

Opus Genetics, Inc. (IRD) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Opus Genetics, Inc. Supplier List (IRD): 10 Verified Suppliers

10Suppliers

20Customers

3Debt Items

20Related Chains

Source-Backed Evidence Depth

Opus Genetics, Inc. (IRD) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

34Total relationships

3Distinct source URLs

9High confidence

0.736Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Opus Genetics, Inc. Suppliers

Ticker	Name	Confidence	Evidence
OPCM-SA-LLC	OPCM-SA-LLC	92%	As previously disclosed, on April 2, 2026, Opus Genetics, Inc., a Delaware corporation (the “Company”), and certain of its subsidiaries as guarantors, entered into a senior secured note purchase agre…
APEXIAN-PHARMACEUTICALS-INC	APEXIAN-PHARMACEUTICALS-INC	90%	In exchange for the patent and other intellectual rights, the Company agreed to certain milestone payments and royalty payments on future sales.
MASSACHUSETTS-EYE-AND-EAR-INFIRMARY	MASSACHUSETTS-EYE-AND-EAR-INFIRMARY	90%	In return for these rights, the Company is obligated to make certain development milestone payments and royalty payments on future sales of such products.
PENN-AND-UF	PENN-AND-UF	90%	In return for these rights, the Company is obligated to make certain development milestone payments and royalty payments on future sales of such products.
MYGN	Myriad Genetics, Inc.	72%	patent application. In addition, such interference, re-examination, opposition, post-grant review, inter partes review, supplemental examination, or revocation proceedings may be costly or time-consu…
MYGN	Myriad Genetics, Inc.	72%	Reciprocal relationship from MYGN graph: Reciprocal relationship from IRD graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from IRD graph: Reciprocal relationship from MYGN gra…
OCUL	Ocular Therapeutix, Inc.	72%	line products, our business will be materially harmed. • Others may discover, develop, or commercialize products similar to those in our pipeline before or more successfully than we do or develop gen…
OCUL	Ocular Therapeutix, Inc.	72%	Reciprocal relationship from OCUL graph: Reciprocal relationship from IRD graph: line products, our business will be materially harmed. • Others may discover, develop, or commercialize products simil…
ORANY	ORANY	72%	Reciprocal relationship from ORANY graph: Reciprocal relationship from IRD graph: place. A request for proposal process, to include small scale process development, technical transfer, and analytical…
ORANY	ORANY	72%	place. A request for proposal process, to include small scale process development, technical transfer, and analytical method development, to identify a manufacturing partner is being conducted. The o…

Opus Genetics, Inc. Customers

Ticker	Name	Confidence	Evidence
VIATRIS	VIATRIS	92%	The Company will be eligible to receive potential additional payments of up to $130 million upon achieving certain specified regulatory or net sales milestones, with the first milestone payment of $1…
MYGN	Myriad Genetics, Inc.	72%	Reciprocal relationship from MYGN graph: Reciprocal relationship from IRD graph: patent application. In addition, such interference, re-examination, opposition, post-grant review, inter partes review…
MYGN	Myriad Genetics, Inc.	72%	patent application. In addition, such interference, re-examination, opposition, post-grant review, inter partes review, supplemental examination, or revocation proceedings may be costly or time-consu…
OCUL	Ocular Therapeutix, Inc.	72%	line products, our business will be materially harmed. • Others may discover, develop, or commercialize products similar to those in our pipeline before or more successfully than we do or develop gen…
OCUL	Ocular Therapeutix, Inc.	72%	Reciprocal relationship from OCUL graph: Reciprocal relationship from IRD graph: Reciprocal relationship from OCUL graph: Reciprocal relationship from IRD graph: line products, our business will be m…
ORANY	ORANY	72%	utics (LNZ100 - 1.75% Aceclidine) and AbbVie (VUITY® (pilocarpine hydrochloride ophthalmic solution) - 1.25%). We are not aware of direct competition for the treatment of DLD following keratorefracti…
ORANY	ORANY	72%	Reciprocal relationship from ORANY graph: Reciprocal relationship from IRD graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from IRD graph: Reciprocal relationship from ORANY …
PCSA	Processa Pharmaceuticals, Inc.	72%	Reciprocal relationship from PCSA graph: Reciprocal relationship from IRD graph: Reciprocal relationship from PCSA graph: Reciprocal relationship from IRD graph: Reciprocal relationship from PCSA gra…
PCSA	Processa Pharmaceuticals, Inc.	72%	2 million and $ 11.0 million, respectively, related to the output of ongoing research and development services and to a much lesser extent royalty payments. Regulatory Milestones under the Viatris Li…
ALICE-CORPORATION-PTY-LTD	ALICE-CORPORATION-PTY-LTD	62%	such interference, re-examination, opposition, post-grant review, inter partes review, supplemental examination, or revocation proceedings may be costly or time-consuming. Thus, any patents that we m…
APEXIAN-PHARMACEUTICALS-INC	APEXIAN-PHARMACEUTICALS-INC	62%	med. • Others may discover, develop, or commercialize products similar to those in our pipeline before or more successfully than we do or develop generic variants of our products even while our produ…
CRAIG-HALLUM-CAPITAL-GROUP-LLC	CRAIG-HALLUM-CAPITAL-GROUP-LLC	62%	product under the MERTK Program. If the Company is unable to achieve certain milestones by certain dates, or otherwise fails to meet its diligence obligations, the Company will be obligated to collab…
LEERINK-PARTNERS-LLC	LEERINK-PARTNERS-LLC	62%	product under the MERTK Program. If the Company is unable to achieve certain milestones by certain dates, or otherwise fails to meet its diligence obligations, the Company will be obligated to collab…
LINCOLN-PARK-CAPITAL-FUND-LLC	LINCOLN-PARK-CAPITAL-FUND-LLC	62%	product under the MERTK Program. If the Company is unable to achieve certain milestones by certain dates, or otherwise fails to meet its diligence obligations, the Company will be obligated to collab…
OCULARIS-PHARMA-LLC	OCULARIS-PHARMA-LLC	62%	med. • Others may discover, develop, or commercialize products similar to those in our pipeline before or more successfully than we do or develop generic variants of our products even while our produ…
OCUPHIRE-PHARMA-INC	OCUPHIRE-PHARMA-INC	62%	med. • Others may discover, develop, or commercialize products similar to those in our pipeline before or more successfully than we do or develop generic variants of our products even while our produ…
OPUSTX-LLC	OPUSTX-LLC	62%	2 million and $ 11.0 million, respectively, related to the output of ongoing research and development services and to a much lesser extent royalty payments. Regulatory Milestones under the Viatris Li…
PLAB	Photronics, Inc.	62%	Reciprocal relationship from PLAB graph: Reciprocal relationship from IRD graph: Reciprocal relationship from PLAB graph: Reciprocal relationship from IRD graph: such interference, re-examination, op…
PROMETHEUS-LABORATORIES-INC	PROMETHEUS-LABORATORIES-INC	62%	such interference, re-examination, opposition, post-grant review, inter partes review, supplemental examination, or revocation proceedings may be costly or time-consuming. Thus, any patents that we m…
REXAHN-PHARMACEUTICALS-INC	REXAHN-PHARMACEUTICALS-INC	62%	med. • Others may discover, develop, or commercialize products similar to those in our pipeline before or more successfully than we do or develop generic variants of our products even while our produ…

Opus Genetics, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
IRD-DEBT-10355	Warrants outstanding: 9.6	90%	xbrl warrant detail from xbrl 2025-12-31.
IRD-DEBT	Debt stack $1.2M	90%	Market cache reports total debt of $1.2M.
IRD-DEBT-10356	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2025-12-31.

Opus Genetics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Opus Genetics, Inc..

Opus Genetics, Inc. Ownership

Holder	Name	Confidence	Evidence
IRD-OWNER-CALIGAN-PARTNERS-LP	Caligan Partners LP	90%	13F overlay lists Caligan Partners LP as top holder; 79 tracked holders.

Opus Genetics, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
BIAF	bioAffinity Technologies, Inc.	100.00	2
TEM	Tempus AI, Inc.	100.00	2
ALLO	Allogene Therapeutics, Inc.	100.00	2
ATYR	aTyr Pharma, Inc.	100.00	2
TPST	Tempest Therapeutics, Inc.	100.00	2
KDK	Kodiak AI, Inc.	100.00	2
CALC	CalciMedica, Inc.	100.00	2
ORANY	ORANGE	100.00	1	['customer', 'supplier']
CABA	Cabaletta Bio, Inc.	100.00	2
ELVN	Enliven Therapeutics, Inc.	100.00	2
IMNM	Immunome, Inc.	100.00	2
HOWL	Werewolf Therapeutics, Inc.	100.00	2
BIOA	BioAge Labs, Inc.	100.00	2
GH	Guardant Health, Inc.	100.00	2
PSNL	Personalis, Inc.	100.00	2
BNTC	Benitec Biopharma Inc.	100.00	2
DSGN	Design Therapeutics, Inc.	100.00	2
BNBX	BNB Plus Corp.	100.00	2
SDGR	Schrödinger, Inc.	100.00	2
DNLI	Denali Therapeutics Inc.	100.00	2

Opus Genetics, Inc. Supply Chain